These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 32572715)

  • 1. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
    Harborg S; Heide-Jørgensen U; Ahern TP; Ewertz M; Cronin-Fenton D; Borgquist S
    Breast Cancer Res Treat; 2020 Aug; 183(1):153-160. PubMed ID: 32572715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.
    Ahern TP; Pedersen L; Tarp M; Cronin-Fenton DP; Garne JP; Silliman RA; Sørensen HT; Lash TL
    J Natl Cancer Inst; 2011 Oct; 103(19):1461-8. PubMed ID: 21813413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
    Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
    J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS
    Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.
    Frechette D; Paquet L; Verma S; Clemons M; Wheatley-Price P; Gertler SZ; Song X; Graham N; Dent S
    Breast Cancer Res Treat; 2013 Aug; 141(1):111-7. PubMed ID: 23942873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
    Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
    Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.
    Ejlertsen B; Jensen MB; Mouridsen HT;
    Acta Oncol; 2014 Feb; 53(2):174-85. PubMed ID: 24219541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study.
    Cold S; Cold F; Jensen MB; Cronin-Fenton D; Christiansen P; Ejlertsen B
    J Natl Cancer Inst; 2022 Oct; 114(10):1347-1354. PubMed ID: 35854422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin use and patterns of breast cancer recurrence in the Malmö Diet and Cancer Study.
    Inasu M; Feldt M; Jernström H; Borgquist S; Harborg S
    Breast; 2022 Feb; 61():123-128. PubMed ID: 34995921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
    Kennecke HF; Olivotto IA; Speers C; Norris B; Chia SK; Bryce C; Gelmon KA
    Ann Oncol; 2007 Jan; 18(1):45-51. PubMed ID: 17030545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
    Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
    Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.